Should You Buy Eli Lilly Stock Before April 10?

Core Insights - Eli Lilly has experienced significant growth, particularly due to its weight loss drug portfolio, which includes tirzepatide marketed as Mounjaro and Zepbound [1][2] - The company has seen over 100% stock growth in the past three years, despite a dip in the current year [3] - A potential catalyst for further growth is the upcoming FDA decision on orforglipron, an oral weight loss candidate, expected on April 10 [6][9] Company Overview - Eli Lilly's tirzepatide has generated over $11 billion in revenue, with triple-digit growth reported for both Mounjaro and Zepbound in the latest quarter [5] - The drug is part of the GLP-1 class, aiding in appetite control and blood sugar management [4] - Orforglipron offers a more convenient oral option compared to injectable drugs, which may enhance its market appeal [7][8] Market Position - Eli Lilly holds a 60% share of the U.S. weight loss drug market, positioning it well for future growth as the market is projected to reach nearly $100 billion by the end of the decade [11] - The convenience of orforglipron could lead to higher margins for the company due to easier manufacturing and storage [8] Investment Considerations - Analysts suggest that the current valuation of Lilly stock is more attractive than in previous months, making it a potentially good investment opportunity [9] - Long-term investment in quality stocks like Lilly is emphasized, regardless of short-term fluctuations [12]